Brief: I-Mab Announces Acceleration Of Givastomig Investment And Leadership Appointments
08/09/2025 13:44
Sept 8 (Reuters) - I-Mab IMAB.O: I-MAB ANNOUNCES ACCELERATION OF GIVASTOMIG INVESTMENT AND LEADERSHIP APPOINTMENTS Source text: ID:nGNX1F1RbR Further company coverage: IMAB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on NovaBridge Biosciences
See all newsBrief: Visara Secures Exclusive Option For Potential Acquisition Of Yol104-2 For Ocular Surface Squamous Neoplasia
Brief: Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis
Brief: Wuhan Hiteck Biological Pharma Grants Visara Exclusive Rights To HT006.2.2 Outside Greater China
Brief: Novabridge Biosciences Announces Expanded Givastomig Safety And Efficacy Data
NovaBridge Biosciences expected to post a loss of 13 cents a share - Earnings Preview